ArticleScientific reports2014
Type IV collagen α1-chain noncollagenous domain blocks MMP-2 activation both in-vitro and in-vivo.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Homeostatic Regulation of Pro-Angiogenic and Anti-Angiogenic Proteins via Hedgehog, Notch Grid, and Ephrin Signaling in Tibial Dyschondroplasia.Animals : an open access journal from MDPI · 2023Review
- Pathogenesis of glaucoma: Extracellular matrix dysfunction in the trabecular meshwork-A review.Clinical & experimental ophthalmology · 2022Review
- Expression of CXCR4 and MMP-2 is associated with poor prognosis in patients with osteosarcoma.Histology and histopathology · 2020Article
- 6-OHDA-Lesioned Adult Zebrafish as a Useful Parkinson's Disease Model for Dopaminergic Neuroregeneration.Neurotoxicity research · 2017Article
- Isolation of a methylated mannose-binding protein from terrestrial worm Enchytraeus japonensis.Glycoconjugate journal · 2017Article
- Three-dimensional collagen matrix induces a mechanosensitive invasive epithelial phenotype.Scientific reports · 2017Article
- MMP-2 Isoforms in Aortic Tissue and Serum of Patients with Ascending Aortic Aneurysms and Aortic Root Aneurysms.PloS one · 2016Article
- Increased precision of orthotopic and metastatic breast cancer surgery guided by matrix metalloproteinase-activatable near-infrared fluorescence probes.Scientific reports · 2015Article
Corrections and comments
- Expression of concern · 2020-02-10Investigation by Company/Institution · Investigation by ORI · Updated to Retraction · · Yakkanti Sudhakar has aka of Yakkanti Akul Sudhakar and Sudhakar Yakkanti; Sudhakar Yakkanti has ORI finding of misconduct; https://ori.hhs.gov/content/case-summary-yakkanti-sudhakar;
- Retraction · 2020-11-26Duplication of/in Image · Investigation by Company/Institution · Investigation by ORI · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Original Data and/or Images not Provided and/or not Available · · Yakkanti Sudhakar has aka of Yakkanti Akul Sudhakar and Sudhakar Yakkanti; Sudhakar Yakkanti has ORI finding of misconduct; https://ori.hhs.gov/content/case-summary-yakkanti-sudhakar;
- Commented on by
- Retracted
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
α1(IV)NC1 inhibits angiogenesis by regulating MAPK activation, this biological function was partly attributed α1(IV)NC1 binding to α1β1-integrin. However, its potent antiangiogenic activity and the molecular targets of α1(IV)NC1 has not been investigated. In the present study, the regulation of MMP-2 activation by α1(IV)NC1 was evaluated. α1β1-integrin which is required for inhibition of angiogenesis is not playing a role in cellular invasion and inhibition of MMP-2 activation by α1(IV)NC1. We found that α1(IV)NC1 binds the CBD of MMP-2 and forming a stable complex that prevents activation of MMP-2. The antiangiogenic activity of α1(IV)NC1 is mediated, in part, by this binding activity. In addition, up-regulation of TIMP-2 by α1(IV)NC1 led to saturation of MT1-MMP binding sites, which in turn led to inhibition of MMP-2 activation. In-vivo studies using α1-integrin null-mice treated with higher doses of α1(IV)NC1 showed integrin independent inhibition of tumor growth and active-MMP-2, without affecting MMP-9, MMP-7 and angiostatin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.